Annual Conference to Fuel Continued Momentum in Journey to Improve Inpatient Glycemic Management and Patient Safety
WALTHAM, Mass. (July 26, 2022) – Glytec, the only provider of cloud-based insulin management software across the continuum of care, today announced details about its annual conference on glycemic management and collaboration, “Time To Target: The Future of Glycemic Management.” Attendees of this event will explore the latest trends in developing best-in-class glycemic management programs. There is no cost to attend the conference, which will be held virtually on October 25-26, 2022.
“After an incredible inaugural event last year, we’re thrilled to bring our industry together again at Time to Target to highlight some amazing work being done at our partner sites to improve insulin management amid a groundswell of change,” said Glytec’s Chief Commercial Officer, John Downey.
The focus on glycemic management has reached a tipping point in health systems across the country. With its new glycemic eCQM metrics, the Centers for Medicare & Medicaid Services (CMS) is making it clear hospitals have a responsibility to improve the management of hyper- and hypoglycemia in hopes of making severe hypoglycemia related to insulin a never event. Moreover, the FDA continues to grant breakthrough designations of CGMs for in-hospital use, and the Endocrine Society recently released new guidelines that offer recommendations for hospitalized patients with diabetes.
These milestone initiatives prove what decades of research have shown: uncontrolled blood glucose in the hospital can negatively impact patient outcomes. Outdated processes and improper insulin dosing can have a wide range of negative impacts, including increased morbidity, mortality and complications that lead to longer lengths of stay, higher readmission rates and increased costs for patients and healthcare systems. Glytec’s annual event aims to mitigate these challenges, educate health systems and improve the quality of care for patients nationwide.
“Insulin management is getting the spotlight it deserves with the new CMS measures being announced this past year and as our industry prepares for next-generation diabetes technology entering the inpatient setting. Health systems still suffer from clinical inertia and are slow to make practice change and our event aims to change that mentality and provide the groundwork for an effective glycemic management program,” added John Downey.
Time to Target sessions will include a mix of informative keynotes, panel discussions, data-driven case studies and innovative product showcases. Featured speakers include:
Guillermo Umpierrez, Chief of Diabetes and Endocrinology at Grady Health Systems
Curtiss B. Cook, Professor of Medicine, Mayo Clinic Alix School of Medicine, and Chair, Division of Endocrinology, Chair, Inpatient Diabetes Subcommittee, and Medical Director, Ambulatory Infusion Services, Mayo Clinic Arizona
Andjela Drincic, Professor, Division of Diabetes, Endocrinology & Metabolism at University of Nebraska Medical Center
Barbara McLean, MN, RN, CCRN, CCNS-BC, NP-BC, FCCM, Critical Care Program Specialist at Grady Health Systems
Sonia Cooper, MSN, BA, RN, NE-BC, Vice President Nurse Executive at Sentara Princess Anne Hospital
Joseph Aloi, Section Professor of Internal Medicine and chief of the Endocrine, Diabetes and Metabolism Section at Wake Forest Baptist Health
Final agenda and speakers to be announced at a later date. All sessions will be available on-demand through November 30, 2022. To learn more about the event and how to register, visit https://www.glytectimetotarget.com.
Glytec is the insulin management software company for healthcare providers focused on improving the quality and cost of care. Its FDA-cleared titration software and proprietary algorithms power the only solution capable of delivering personalized diabetes treatment recommendations across the continuum of care, from hospital to home. With ongoing support from its team of doctors, nurses and technologists headquartered outside of Boston, Glytec improves outcomes and controls costs for the large population of patients requiring insulin treatment – including those with and without a diagnosis of diabetes. For more information, follow Glytec on Twitter (@Glytec) and LinkedIn, or visit www.GlytecSystems.com.
fama PR for Glytec
MAR-0000891 Rev 1.0